Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ifosfamide-induced hyperpigmentation

M E Teresi1, D J Murry, A S Cornelius

  • 1Division of Clinical/Hospital Pharmacy, University of Iowa College of Pharmacy, Iowa City 52242-1123.

Cancer
|May 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and validation of a liquid chromatography-mass spectrometric assay for simultaneous determination of tacrolimus and 13-O-desmethyl tacrolimus in rat kidney tissue.

Journal of pharmaceutical and biomedical analysis·2017
Same author

Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University.

Annals of oncology : official journal of the European Society for Medical Oncology·2005
Same author

Hydrolysis of capecitabine to 5'-deoxy-5-fluorocytidine by human carboxylesterases and inhibition by loperamide.

The Journal of pharmacology and experimental therapeutics·2005
Same author

Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway.

The pharmacogenomics journal·2004
Same author

Pharmacokinetics and metabolism of oral midazolam in preterm infants.

British journal of clinical pharmacology·2002
Same author

Meropenem pharmacokinetics in children and adolescents receiving hemodialysis.

Pediatric nephrology (Berlin, Germany)·2002

Ifosfamide, a chemotherapy drug, can cause skin pigment changes, similar to cyclophosphamide. This case report highlights an uncommon adverse effect of ifosfamide in a child with Wilms tumor.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Cyclophosphamide, a chemotherapy agent, is known to cause nail banding and skin hyperpigmentation.
  • Ifosfamide, a related chemotherapy drug, has not been previously reported to cause similar pigmentary changes.

Observation:

  • A 5-year-old patient undergoing treatment for relapsed Wilms tumor experienced skin pigment alterations.
  • The patient was treated with a combination of ifosfamide, MESNA, and etoposide.

Findings:

  • This case presents the first reported instance of ifosfamide-induced skin pigment changes.
  • A literature review confirmed no prior reports linking ifosfamide to pigmentary side effects.

Implications:

  • Healthcare providers should be aware of this potential uncommon adverse effect of ifosfamide.

Related Experiment Videos

  • Further research may explore the correlation between renal dysfunction and ifosfamide-induced pigmentary changes.